Literature DB >> 1859048

Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome.

T M Hyers1, S M Tricomi, P A Dettenmeier, A A Fowler.   

Abstract

Tumor necrosis factor (TNF) was measured antigenically and functionally in serum and bronchoalveolar lavage fluid (BAL) of patients with ARDS and those at high risk for ARDS. Of 22 patients with ARDS, 14 had sepsis or serious infection as the major clinical predisposition, and 10 of 20 high-risk patients had sepsis or serious infection. Mean levels of TNF in serum of patients with ARDS and high risk showed a trend toward elevation but were not significantly higher than mean serum levels in normal subjects. Mean levels of TNF in BAL of ARDS patients (242 +/- 126 pg/ml) were significantly higher than in normal subjects (9 +/- 5 pg/ml), p less than 0.05. Antigenic levels of TNF were undetectable in approximately half the patients with ARDS or the high-risk state. Levels of TNF in BAL appeared to be highest in the first day of ARDS. There appeared to be no relationship between levels of TNF in serum or BAL and subsequent mortality. However, serum levels of TNF were significantly higher in septic patients than in nonseptic patients, whereas this difference was not apparent in BAL. These results show that functional and antigenic elevations of TNF are present in BAL and perhaps in serum of patients with ARDS or with the high-risk state.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859048     DOI: 10.1164/ajrccm/144.2.268

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  31 in total

1.  Death receptors mediate the adverse effects of febrile-range hyperthermia on the outcome of lipopolysaccharide-induced lung injury.

Authors:  Anne B Lipke; Gustavo Matute-Bello; Raquel Herrero; Venus A Wong; Stephen M Mongovin; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-22       Impact factor: 5.464

Review 2.  The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

Authors:  M Messent; M J Griffiths
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 3.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 4.  Biomarkers in acute lung injury.

Authors:  Maneesh Bhargava; Chris H Wendt
Journal:  Transl Res       Date:  2012-02-07       Impact factor: 7.012

5.  N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells.

Authors:  S Hashimoto; Y Gon; K Matsumoto; I Takeshita; T Horie
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 6.  The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling.

Authors:  A Artigas; G R Bernard; J Carlet; D Dreyfuss; L Gattinoni; L Hudson; M Lamy; J J Marini; M A Matthay; M R Pinsky; R Spragg; P M Suter
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

7.  Tumor necrosis factor induced acute lung leak in rats: less than with interleukin-1.

Authors:  Y Koh; B M Hybertson; E K Jepson; J E Repine
Journal:  Inflammation       Date:  1996-10       Impact factor: 4.092

8.  Streptococcal cysteine protease augments lung injury induced by products of group A streptococci.

Authors:  T P Shanley; D Schrier; V Kapur; M Kehoe; J M Musser; P A Ward
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

9.  Role of mesenchymal cell death in lung remodeling after injury.

Authors:  V A Polunovsky; B Chen; C Henke; D Snover; C Wendt; D H Ingbar; P B Bitterman
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 10.  Acute respiratory distress syndrome in the septic surgical patient.

Authors:  Jose L Balibrea; Javier Arias-Díaz
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.